COL19A1 is a predictive biomarker for the responsiveness of esophageal squamous cell carcinoma patients to immune checkpoint therapy

BACKGROUND: The use of neoadjuvant immunotherapy plus chemotherapy has revolutionized the management of esophageal squamous cell carcinoma (ESCC) patients. Nevertheless, patients who would maximally benefit from these therapies have not been identified. METHODS: We collected postoperative specimens...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jian‐Hua, Lin, Ju‐Ze, Qiu, Qianhui, Zhu, Changbin, Li, Weiwei, Li, Qian, Huang, Zhan, Xia, Xueer, Qiao, Guibin, Tang, Jiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175035/
https://www.ncbi.nlm.nih.gov/pubmed/37005910
http://dx.doi.org/10.1111/1759-7714.14873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175035/
https://www.ncbi.nlm.nih.gov/pubmed/37005910
http://dx.doi.org/10.1111/1759-7714.14873

Ejemplares similares